Brief: GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
23/10/2025 14:07
Oct 23 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA PROVIDES ENROLLMENT UPDATE ON GTB-3650 PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD33 EXPRESSING HEMATOLOGIC MALIGNANCIES GT BIOPHARMA INC - ADVANCES TO COHORT 4 WITH 10 UG/KG/DAY DOSE GT BIOPHARMA INC - SCREENING PATIENTS FOR COHORT 4, DOSING TO START SOON GT BIOPHARMA INC - NEXT UPDATE EXPECTED IN Q1 2026 WITH DOSE ESCALATION Source text: ID:nGNX1MpMR5 Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))